NCT06560645 2026-02-02
A Study of PRT7732, an Oral SMARCA2 Degrader, in Patients With Advanced or Metastatic Solid Tumors With a SMARCA4 Mutation
Prelude Therapeutics
Phase 1 Terminated
Prelude Therapeutics
Blueprint Medicines Corporation
Inhibrx Biosciences, Inc
Roswell Park Cancer Institute
Case Comprehensive Cancer Center